-
Mashup Score: 4
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a summary of her talk presented recently at the Chemotherapy Foundation Symposium. Dr. Jhaveri discusses important data about the activity of antibody-drug conjugates in patients with breast cancer, including breast
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer - 1 month(s) ago
Vered Stearns, MD, is the Director for Translational Breast Cancer Research  in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast cancer. Triple-negative breast cancer affects a small p ortion of all breast cancer subtypes, representing about 15% of tumors. It is more common in younger women, in black African American women, and those who are
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer https://t.co/SYUxSEaNjs #bcsm #breastcancer #oncology @ChemotherapyFnd #CFS2024 #CFS24 @WeillCornell @WCMBreastCenter
-
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer https://t.co/GrCBPLhJS2 #bcsm #breastcancer #oncology @ChemotherapyFnd #CFS2024 #CFS24 @WeillCornell @MSKCancerCenter